WOW. Unglaubliche Ehre! Mein Roman „Das Stoffuniversum“ ist für den Phantastik-Literaturpreis Seraph nominiert. Vielen Dank! #Seraph #Phantastik #Literaturpreis

📢 Open Call! Applications for a Professorship in Biochemistry are now possible. Read more ➡️ tinyurl.com/yvcu7re7 MedUni Wien

Reminder that the US built some of the greatest train stations ever seen. These are the most beautiful (thread) 🧵

Otto Warburg's grant application from 1921 is just one sentence – “I require 10,000 marks” – and it was fully funded.

Great opportunity in Vienna

Opportunity in a world-class institute in beautiful Vienna!

Genetic dependencies associated with transcription factor activities in human cancer cell lines: Cell Reports cell.com/cell-reports/f…

Where we are in the sci-fi movie timeline [📊 danmeth. com]

Concurrent with #WCLC24 Presidential Symposium: Zongertinib (BI 1810631) an Irreversible #HER2 TKI Spares EGFR Signaling & Improves Therapeutic Response in Preclinical Models & Patients with HER2-driven Cancers. Birgit Wilding,et al. bit.ly/3Zc6gKl Ralph Neumüller Boehringer Ingelheim

#NEWS: The results of our research on targeting mutated HER2, a protein regulating cell growth, have been published in Cancer Discovery. Annually, more than 40,000 people are diagnosed with HER2-mutated non-small cell lung cancer. Learn more here: bit.ly/3zbFJlG

Zongertinib Demonstrates Clinically Meaningful Efficacy in HER2-Mutated NSCLC IASLC #WCLC24 #lcsm onclive.com/view/zongertin…

Check out our new paper in Cancer Discovery Cancer Discovery. Targeting mutated #HER2 with a novel TKI in NSCLC and other HER2-driven cancers. aacrjournals.org/cancerdiscover…

So great to meet up with Daniel Gerlach at #ESMO24! And be sure to read about the irreversible HER2 TKI he and colleagues very recently published in Cancer Discovery 👉🏻 aacrjournals.org/cancerdiscover…

Concurrent with #WCLC24 Presidential Symposium: Zongertinib (BI 1810631) an Irreversible #HER2 TKI Spares EGFR Signaling & Improves Therapeutic Response in Preclinical Models & Patients with HER2-driven Cancers. Birgit Wilding,et al. bit.ly/3B6gKRj Ralph Neumüller Boehringer Ingelheim

Happy to see our paper in print Cancer Discovery Check it out! Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers aacrjournals.org/cancerdiscover…

From the January issue: Zongertinib (BI 1810631), an Irreversible #HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-driven Cancers brnw.ch/21wQt3N By Birgit Wilding, Ralph Neumüller, and colleagues Boehringer Ingelheim

Discovery of Carbodiimide Warheads to Selectively and Covalently Target Aspartic Acid in KRASG12D | Journal of the American Chemical Society pubs.acs.org/doi/abs/10.102…